home / stock / amrx / amrx news


AMRX News and Press, Amneal Pharmaceuticals Inc. Class A

Stock Information

Company Name: Amneal Pharmaceuticals Inc. Class A
Stock Symbol: AMRX
Market: NASDAQ
Website: amneal.com

Menu

AMRX AMRX Quote AMRX Short AMRX News AMRX Articles AMRX Message Board
Get AMRX Alerts

News, Short Squeeze, Breakout and More Instantly...

AMRX - Amneal outlines 2026 guidance with 12% to 24% EPS growth target, signals acceleration in affordable medicines

2026-02-27 10:18:38 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Mor...

AMRX - Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript

2026-02-27 10:17:56 ET Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call February 27, 2026 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript

AMRX - Amneal (AMRX) Q4 2025 Earnings Call Transcript

2026-02-27 09:59:00 ET Image source: The Motley Fool. Friday, Feb. 27, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

AMRX - Amneal Pharmaceuticals Non-GAAP EPS of $0.21 beats by $0.03, revenue of $814M beats by $6.68M

2026-02-27 06:09:01 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Am...

AMRX - Expected US Company Earnings on Friday, February 27th, 2026

Sunstone Hotel Investors Inc. (SHO) is expected to report $0.18 for Q4 2025 GT Biopharma Inc. (GTBP) is expected to report $-0.22 for Q4 2025 Global Partners LP representing Limited Partner Interests (GLP) is expected to report $0.6 for Q4 2025 4D Molecular Therapeutics Inc. (FDMT) is...

AMRX - Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025...

AMRX - Amneal Pharmaceuticals Q4 2025 Earnings Preview

2026-02-26 10:41:29 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Am...

AMRX - Earnings week ahead: NVDA, CRM, HD, BIDU, LOW, DELL, SNOW, AMC, ZM, and more

2026-02-22 08:07:08 ET The last week of February brings another packed stretch of earnings, with a mix of megacap technology leaders, consumer bellwethers, energy producers, financial firms, and high-growth disruptors set to report.... Read the full article on Seeking Alpha For ...

AMRX - Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market

Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market Canada NewsWire ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. VANCOUVER, BC , Feb. 13, 2026 /CNW/ -- Equity-Insider.com News Commentary – The global health and wellness sector is entering 2...

AMRX - Amneal initiates nationwide settlement for opioid-related claims

2026-01-29 11:23:03 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Am...

Next 10